Cambrex’s acquisition of Q1 Scientific expands the company’s storage services in the European market.
Cambrex announced on June 1, 2022 that it had acquired Q1 Scientific, an Irish provider of environmentally-controlled current good manufacturing practices (cGMP) stability storage services for the pharmaceutical, medical device, and life science industries.
According to a company press release, Q1’s Scientific's cGMP facility is validated to meet specific storage requirements for the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human (ICH). The 20,000 ft² facility has approximately 40 walk-in stability storage chambers, reach-in freezers, and stability units, as well as ultra-low temperature freezers for biologic therapies. In addition to these storage capabilities, the company also provides sample management and transport services.
“Stability storage and testing is a critical component of drug development and commercialization of new therapies.,” said Tom Loewald, CEO, Cambrex, in the press release. “This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market.”
“We’re pleased to join Cambrex as we continue to provide leading stability storage services to our current customers,” said Stephen Delaney, CEO, Q1 Scientific, in the press release. “With Cambrex’s scientific expertise and scale, we’ll be able to accelerate our growth and offer an integrated suite of analytical services, providing a full range of market-leading solutions for our customers.”
Source: Cambrex
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.